Global Benign Prostatic Hyperplasia (BPH) Treatment Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Table of Contents

1 Benign Prostatic Hyperplasia (BPH) Treatment Market Overview

• 1.1 Product Overview and Scope of Benign Prostatic Hyperplasia (BPH) Treatment
• 1.2 Classification of Benign Prostatic Hyperplasia (BPH) Treatment by Types
  • 1.2.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Comparison by Types (2019-2024)
  • 1.2.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Types in 2018
  • 1.2.3 Drugs
  • 1.2.4 Invasive Procedures
  • 1.2.5 Device
• 1.3 Global Benign Prostatic Hyperplasia (BPH) Treatment Market by Application
  • 1.3.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Market Share Comparison by Applications (2014-2024)
  • 1.3.2 Hospitals
  • 1.3.3 Clinics
  • 1.3.4 Other
• 1.4 Global Benign Prostatic Hyperplasia (BPH) Treatment Market by Regions
  • 1.4.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size (Million USD) Comparison by Regions (2014-2024)
  • 1.4.1 North America (USA, Canada and Mexico) Benign Prostatic Hyperplasia (BPH) Treatment Status and Prospect (2014-2024)
  • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Benign Prostatic Hyperplasia (BPH) Treatment Status and Prospect (2014-2024)
  • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Benign Prostatic Hyperplasia (BPH) Treatment Status and Prospect (2014-2024)
  • 1.4.4 South America (Brazil, Argentina, Colombia) Benign Prostatic Hyperplasia (BPH) Treatment Status and Prospect (2014-2024)
  • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Benign Prostatic Hyperplasia (BPH) Treatment Status and Prospect (2014-2024)
• 1.5 Global Market Size of Benign Prostatic Hyperplasia (BPH) Treatment (2014-2024)

2 Manufacturers Profiles

• 2.1 Astellas Pharma
  • 2.1.1 Business Overview
  • 2.1.2 Benign Prostatic Hyperplasia (BPH) Treatment Type and Applications
    • 2.1.2.1 Product A
    • 2.1.2.2 Product B
  • 2.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.2 Eli Lilly
  • 2.2.1 Business Overview
  • 2.2.2 Benign Prostatic Hyperplasia (BPH) Treatment Type and Applications
    • 2.2.2.1 Product A
    • 2.2.2.2 Product B
  • 2.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.3 GlaxoSmithKline
  • 2.3.1 Business Overview
  • 2.3.2 Benign Prostatic Hyperplasia (BPH) Treatment Type and Applications
    • 2.3.2.1 Product A
    • 2.3.2.2 Product B
  • 2.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.4 Sanofi
  • 2.4.1 Business Overview
  • 2.4.2 Benign Prostatic Hyperplasia (BPH) Treatment Type and Applications
    • 2.4.2.1 Product A
    • 2.4.2.2 Product B
  • 2.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.5 Novartis
  • 2.5.1 Business Overview
  • 2.5.2 Benign Prostatic Hyperplasia (BPH) Treatment Type and Applications
    • 2.5.2.1 Product A
    • 2.5.2.2 Product B
  • 2.5.3 Novartis Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.6 Teva
  • 2.6.1 Business Overview
  • 2.6.2 Benign Prostatic Hyperplasia (BPH) Treatment Type and Applications
    • 2.6.2.1 Product A
    • 2.6.2.2 Product B
  • 2.6.3 Teva Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.7 Boston Scientific
  • 2.7.1 Business Overview
  • 2.7.2 Benign Prostatic Hyperplasia (BPH) Treatment Type and Applications
    • 2.7.2.1 Product A
    • 2.7.2.2 Product B
  • 2.7.3 Boston Scientific Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.8 NxThera, Inc.(Rezum)
  • 2.8.1 Business Overview
  • 2.8.2 Benign Prostatic Hyperplasia (BPH) Treatment Type and Applications
    • 2.8.2.1 Product A
    • 2.8.2.2 Product B
  • 2.8.3 NxThera, Inc.(Rezum) Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.9 NeoTract, Inc.(UroLift)
  • 2.9.1 Business Overview
  • 2.9.2 Benign Prostatic Hyperplasia (BPH) Treatment Type and Applications
    • 2.9.2.1 Product A
    • 2.9.2.2 Product B
  • 2.9.3 NeoTract, Inc.(UroLift) Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2018)

3 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Competition, by Players

• 3.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Share by Players (2014-2019)
• 3.2 Market Concentration Rate
  • 3.2.1 Top 5 Benign Prostatic Hyperplasia (BPH) Treatment Players Market Share
  • 3.2.2 Top 10 Benign Prostatic Hyperplasia (BPH) Treatment Players Market Share
• 3.3 Market Competition Trend

4 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Regions

• 4.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Market Share by Regions
• 4.2 North America Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
• 4.3 Europe Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
• 4.4 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
• 4.5 South America Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
• 4.6 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)

5 North America Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Countries

• 5.1 North America Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Countries (2014-2019)
• 5.2 USA Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
• 5.3 Canada Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
• 5.4 Mexico Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)

6 Europe Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Countries

• 6.1 Europe Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Countries (2014-2019)
• 6.2 Germany Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
• 6.3 UK Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
• 6.4 France Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
• 6.5 Russia Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
• 6.6 Italy Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)

7 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Countries

• 7.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Countries (2014-2019)
• 7.2 China Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
• 7.3 Japan Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
• 7.4 Korea Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
• 7.5 India Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
• 7.6 Southeast Asia Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)

8 South America Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Countries

• 8.1 South America Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Countries (2014-2019)
• 8.2 Brazil Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
• 8.3 Argentina Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
• 8.4 Colombia Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)

9 Middle East and Africa Revenue Benign Prostatic Hyperplasia (BPH) Treatment by Countries

• 9.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Countries (2014-2019)
• 9.2 Saudi Arabia Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
• 9.3 UAE Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
• 9.4 Egypt Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
• 9.5 Nigeria Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
• 9.6 South Africa Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)

10 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Segment by Type

• 10.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Market Share by Type (2014-2019)
• 10.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Forecast by Type (2019-2024)
• 10.3 Drugs Revenue Growth Rate (2014-2024)
• 10.4 Invasive Procedures Revenue Growth Rate (2014-2024)
• 10.5 Device Revenue Growth Rate (2014-2024)

11 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Segment by Application

• 11.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Application (2014-2019)
• 11.2 Benign Prostatic Hyperplasia (BPH) Treatment Market Forecast by Application (2019-2024)
• 11.3 Hospitals Revenue Growth (2014-2019)
• 11.4 Clinics Revenue Growth (2014-2019)
• 11.5 Other Revenue Growth (2014-2019)

12 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Forecast (2019-2024)

• 12.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Forecast (2019-2024)
• 12.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Forecast by Regions (2019-2024)
• 12.3 North America Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Forecast (2019-2024)
• 12.4 Europe Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Forecast (2019-2024)
• 12.5 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Forecast (2019-2024)
• 12.6 South America Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Forecast (2019-2024)
• 12.7 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology